Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
BC Cancer Agency · Jewish General Hospital · +8 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,112
total citations
- FWCI
- 40.45
- Percentile
- 100%
- References
- 34
Citations per year
Authors
14Topics & keywords
Topics
Keywords
- Medicine
- Olaparib
- Internal medicine
- Tolerability
- Breast cancer
- Ovarian cancer
- Oncology
- BRCA mutation
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.